Capivasertib (Truqap, AstraZeneca) is indicated 'in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0 or 1+, or IHC 2+/ISH-) locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine based regimen'.
The dosage schedule is available in the summary of product characteristics for capivasertib.
Capivasertib costs £5,850 per 64‑pack of 200‑mg tablets (excluding VAT; company submission). Fulvestrant costs £55.32 for 2 pre-filled syringes of 250 mg/5 ml solution for injection (excluding VAT; drugs and pharmaceutical electronic market information tool [eMIT], accessed December 2024). The list price for 12 months of treatment is £77,088.12.
The company has a commercial arrangement. This makes capivasertib plus fulvestrant available to the NHS with a discount. The size of the discount is commercial in confidence.